FIFTH AMENDMENT TO DEVELOPMENT
AND COMMERCIALIZATION AGREEMENT
THIS FIFTH AMENDMENT TO DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT (this “Fifth Amendment”) is made as of the 27th day of October, 2012, by and between Artann
Laboratories, Inc. (“Artann”), a New Jersey corporation and ProUroCare Medical Inc. (“ProUroCare”), a Nevada
A. Artann and ProUroCare (“the Parties”)
entered into a Development and Commercialization Agreement (“the Development Agreement”) on July 25, 2008 relating
to a Prostate Mechanical Imaging System (the “PMI System”).
B. The Parties have amended the Development Agreement
four (4) times since July 25, 2008, and have put forward their best efforts and performed their obligations in full compliance
to date with the Development Agreement as so amended.
C. The Parties now wish to further amend the Development
Agreement as provided herein.
Now, therefore, in consideration of the
covenants and agreements set forth herein and for valuable consideration, receipt of which is hereby acknowledged, the Parties
mutually agree as follows:
Terms used in this Fifth Amendment but not
defined or redefined in this Fifth Amendment shall have the meanings ascribed thereto in the Development Agreement and all prior
PAYMENT FOR DEVELOPMENT ACTIVITIES
A new Section 3.3(d) shall be added which
shall read as follows:
||Everything in the Development Agreement and all prior Amendments thereto notwithstanding, any and all payments which were to be due and payable on October 27, 2012 shall become due and payable one (1) month later; i.e., November 27, 2012. The total dollar amount which shall become due and payable on November 27, 2012, shall be the total amount which was to be due and payable on October 27, 2012 plus simple interest accrued thereupon at the rate of twenty percent (20%) per annum.”|
IN WITNESS THEREOF, the Parties, intending
to be legally bound, have caused this Amendment to be executed by their duly authorized officers, as of the effective date of this
|PROUROCARE MEDICAL INC.
||ARTANN LABORATORIES, INC.
|/s/ Richard Thon
||/s/ Noune Sarvazyan
|Title: Chief Financial Officer
||Title: Chief Executive Officer